Yichao Geng1, Qiuning Zhang2,3, Shuangwu Feng1, Chengcheng Li1, Lina Wang1, Xueshan Zhao1, Zhen Yang4, Zheng Li2,3, Hongtao Luo2,3, Ruifeng Liu2,3, Bing Lu5,6, Xiaohu Wang1,2,3. 1. The First School of Clinical Medicine, Lanzhou University, Lanzhou, China. 2. Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China. 3. Lanzhou Heavy Ion Hospital, Lanzhou, China. 4. Basic Medical College, Lanzhou University, Lanzhou, China. 5. Department of Oncology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China. 6. Department of Oncology, Guizhou Cancer Hospital, Guiyang, China.
Abstract
BACKGROUND: A combination of programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non-small-cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a systematic review and meta-analysis to summarize the related research. METHODS: We searched the China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all the relevant studies. The Stata software, version 12.0 was used for the meta-analysis. RESULTS: The study included 20 clinical trials that enrolled 2027 patients with NSCLC. Compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT was associated with prolonged overall survival (OS) (1-year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35-2.33, p = 0.000; 2-year OS: OR 1.77, 95% CI 1.35-2.33, p = 0.000) and progression-free survival (PFS) (0.5-year PFS: OR 1.83, 95% CI 1.13-2.98, p = 0.014; 1-year PFS: OR 2.09, 95% CI 1.29-3.38, p = 0.003; 2-year PFS: OR 2.47, 95% CI 1.13-5.37, p = 0.023). Combination therapy also improved the objective response rate (OR 2.76, 95% CI 1.06-7.19, p = 0.038) and disease control rate (OR 1.80, 95% CI 1.21-2.68, p = 0.004). This meta-analysis showed that compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT did not increase the serious adverse event rates (≥grade 3); however, this approach increased the rate of grade 1-2 immune-related or radiation pneumonitis. Subgroup analyses revealed that the sequence of PD-1/PD-L1 inhibitors followed RT outperformed in which concurrent PD-1/PD-L1 inhibitor and RT followed PD-1/PD-L1 inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with PD-1/PD-L1 inhibitors may be more effective than a combination of conventional RT with PD-1/PD-L1 inhibitors in patients with advanced NSCLC. CONCLUSION: Combination therapy using PD-1/PD-L1 inhibitors and RT may improve OS, PFS, and tumor response rates without an increase in serious adverse events in patients with advanced NSCLC. However, combination therapy was shown to increase the incidence of mild pneumonitis.
BACKGROUND: A combination of programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non-small-cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a systematic review and meta-analysis to summarize the related research. METHODS: We searched the China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all the relevant studies. The Stata software, version 12.0 was used for the meta-analysis. RESULTS: The study included 20 clinical trials that enrolled 2027 patients with NSCLC. Compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT was associated with prolonged overall survival (OS) (1-year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35-2.33, p = 0.000; 2-year OS: OR 1.77, 95% CI 1.35-2.33, p = 0.000) and progression-free survival (PFS) (0.5-year PFS: OR 1.83, 95% CI 1.13-2.98, p = 0.014; 1-year PFS: OR 2.09, 95% CI 1.29-3.38, p = 0.003; 2-year PFS: OR 2.47, 95% CI 1.13-5.37, p = 0.023). Combination therapy also improved the objective response rate (OR 2.76, 95% CI 1.06-7.19, p = 0.038) and disease control rate (OR 1.80, 95% CI 1.21-2.68, p = 0.004). This meta-analysis showed that compared with non-combination therapy, combination therapy using PD-1/PD-L1 inhibitors and RT did not increase the serious adverse event rates (≥grade 3); however, this approach increased the rate of grade 1-2 immune-related or radiation pneumonitis. Subgroup analyses revealed that the sequence of PD-1/PD-L1 inhibitors followed RT outperformed in which concurrent PD-1/PD-L1 inhibitor and RT followed PD-1/PD-L1 inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with PD-1/PD-L1 inhibitors may be more effective than a combination of conventional RT with PD-1/PD-L1 inhibitors in patients with advanced NSCLC. CONCLUSION: Combination therapy using PD-1/PD-L1 inhibitors and RT may improve OS, PFS, and tumor response rates without an increase in serious adverse events in patients with advanced NSCLC. However, combination therapy was shown to increase the incidence of mild pneumonitis.
Authors: Miranda Cumpston; Tianjing Li; Matthew J Page; Jacqueline Chandler; Vivian A Welch; Julian Pt Higgins; James Thomas Journal: Cochrane Database Syst Rev Date: 2019-10-03
Authors: Kamran A Ahmed; Sungjune Kim; John Arrington; Arash O Naghavi; Thomas J Dilling; Ben C Creelan; Scott J Antonia; Jimmy J Caudell; Louis B Harrison; Solmaz Sahebjam; Jhanelle E Gray; Arnold B Etame; Peter A Johnstone; Michael Yu; Bradford A Perez Journal: J Neurooncol Date: 2017-05-02 Impact factor: 4.130
Authors: Willemijn S M E Theelen; Heike M U Peulen; Ferry Lalezari; Vincent van der Noort; Jeltje F de Vries; Joachim G J V Aerts; Daphne W Dumoulin; Idris Bahce; Anna-Larissa N Niemeijer; Adrianus J de Langen; Kim Monkhorst; Paul Baas Journal: JAMA Oncol Date: 2019-09-01 Impact factor: 31.777
Authors: Bairavi Shankar; Jiajia Zhang; Abdul Rafeh Naqash; Patrick M Forde; Josephine L Feliciano; Kristen A Marrone; David S Ettinger; Christine L Hann; Julie R Brahmer; Biagio Ricciuti; Dwight Owen; Yukihiro Toi; Paul Walker; Gregory A Otterson; Sandip H Patel; Shunichi Sugawara; Jarushka Naidoo Journal: JAMA Oncol Date: 2020-12-01 Impact factor: 31.777